If If If we get approval OR accelerated approval Or conditional approval for pediatric SR aGvHD and the insurers are good for circa US$500,000 per patient.
Then the stock for the adult trial would be diverted to pediatric sales immediately?
How much stock of Rem-l would the company still be holding given both adult and pediatric EAP's have been using the reserves?
What sales would you estimate for immediate orders to the 15 major hospitals?
Pondering Reg
Mesoblast stock(rock)-take March 2024, page-170
-
- There are more pages in this discussion • 106 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.21 |
Change
0.040(3.42%) |
Mkt cap ! $1.381B | |||
| Open | High | Low | Value | Volume |
| $1.17 | $1.22 | $1.17 | $5.683M | 4.776M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 20000 | $1.21 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.21 | 19746 | 3 |
View Market Depth
| Last trade - 16.10pm 01/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |